Sirf Bio Private Limited - Due diligence report

A 360° intelligence report on Sirf Bio Private Limited: trust score, financial health, credit view, compliance, directors, growth and distre…

2014-12-18 Hyderabad, Telangana Active Unlisted Active Compliant
Share
SB Sirf Bio Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Sirf Bio Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
63/100
Trust Score
Moderate

Sirf Bio Private Limited is assessed as Moderate with a Trust Score of 63/100. Sirf Bio Private Limited is an active private limited indian non-government company incorporated in 2014, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Sirf Bio Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
63/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
90/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
5/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
40/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 90/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 2 auditor resignation(s) filed - latest: MURTHY & PRASAD & CO on 2023-07-26.
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SURESH GAJANAN PATWARDHAN 01234567 Director 01/04/2018 6 yrs Approved
SHESHEER KUMAR MUNPALLY 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Huwel Lifesciences Private Limited
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 3 transfer(s)

Promoters hold the largest single block of equity - exact percentages are part of the full report.

Group entityRelationship% held
Huwel Lifesciences Private Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 40
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Operating for 11+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Negative net worth.
2 auditor resignation(s) on record - review the stated reasons.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence67/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment44/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view46/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 11 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
31 Mar 2022
Share transfer (FY 2022)
3334.00000000 shares to Private Limited Huwel Lifesciences
Share transfer (FY 2022)
1732.00000000 shares to Private Limited Huwel Lifesciences
30 Mar 2022
Director ceased
ASHOK GAJANAN PATWARDHAN
31 Mar 2020
Share transfer (FY 2020)
3334.00000000 shares to SHESHEER KUMAR MUNPALLY
31 Mar 2019
Director ceased
SASTRI RAMAKRISHNA RAJYALAXMI NARASIMHA YANAMANDRA
30 Sep 2017
Director ceased
SHESHEER KUMAR MUNPALLY
07 Aug 2017
Director appointed
SHESHEER KUMAR MUNPALLY (Director)
18 Dec 2014
Incorporated
Registered with Roc Hyderabad
Director appointed
SURESH GAJANAN PATWARDHAN (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold the largest single block of equity as per the FY 2023 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Hueframe Technologies Private Limited U72200UP2017PTC096677 Noida, Uttar Pradesh, India
Infiniteai Technology Private Limited U74999GJ2021PTC127588 Rajkot, Gujarat, India
Network Magical Consulting Private Limited U64120DL2020PTC370183 Delhi, Delhi, India
360 Companybecho Private Limited U74999PN2022PTC207575 Pune, Maharashtra, India
Supreme Automobiles Private Limited U50101OR1995PTC004033 Balasore, Orissa, India
Kiacart Private Limited U72900TN2022PTC149217 Chennai, Tamil Nadu, India
Dhruv Energy Private Limited U40300UP2016PTC083146 Noida, Uttar Pradesh, India
Kiaraa Pay Technology Private Limited U62090DL2022PTC404887 Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Sirf Bio Private Limited before audits and certifications: compliance score 90/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Sirf Bio Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Sirf Bio Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 63/100, distress signals and MSME payment-delay disclosures - know whether Sirf Bio Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Sirf Bio Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Sirf Bio Private Limited an active company?

Sirf Bio Private Limited has MCA status “Active” with a compliance score of 90/100 (Low Risk).

Is Sirf Bio Private Limited financially healthy?

Sirf Bio Private Limited has a Financial Health Score of 5/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Sirf Bio Private Limited?

Its overall Trust Score is 63/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Sirf Bio Private Limited?

The ultimate holding entity is Huwel Lifesciences Private Limited. 2 active director(s) are on record.

Does Sirf Bio Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Sirf Bio Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 90/100 (Low Risk).

Is it risky to lend to Sirf Bio Private Limited?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.